Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia

PURPOSE: This post-hoc analysis examined whether age modified the efficacy and safety of alirocumab, a PCSK9 inhibitor, in patients with heterozygous familial hypercholesterolemia (HeFH), using pooled data from four 78-week placebo-controlled phase 3 trials (ODYSSEY FH I, FH II, LONG TERM, and HIGH...

Descripción completa

Detalles Bibliográficos
Autores principales: Ginsberg, Henry N., Tuomilehto, Jaakko, Hovingh, G. Kees, Cariou, Bertrand, Santos, Raul D., Brown, Alan S., Sanganalmath, Santosh K., Koren, Andrew, Thompson, Desmond, Raal, Frederick J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433806/
https://www.ncbi.nlm.nih.gov/pubmed/30734207
http://dx.doi.org/10.1007/s10557-019-06852-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433806/
https://www.ncbi.nlm.nih.gov/pubmed/30734207
http://dx.doi.org/10.1007/s10557-019-06852-6

Ejemplares similares